Orchid Chemicals in joint venture with US firmIllustrative image – not actual.

Orchid Chemicals & Pharmaceuticals has formed an equal joint venture with California-based Bexel Biotechnology, for drug research.

 

The company will focus on developing new drugs for diabetes, obesity and inflammation, which it hopes to license out to global drug manufacturers.

 

Over the next 3 years, Orchid plans to invest US$ 8 million (approx. Rs.38 crore) as equity in the California-based joint venture, Bexel Pharmaceuticals. During 2002-03, the company plans to invest a total of US$ 2 million (approx. Rs.10 crore) and US$ 3 million (approx. Rs.14 crore) each in the following 2 years.

← All latest storiesBack to top →